<DOC>
	<DOCNO>NCT00578825</DOCNO>
	<brief_summary>The study aim examine whether combination Lopinavir/Ritonavir plus Ribavirin treatment severe acute respiratory syndrome ( SARS ) superior placebo .</brief_summary>
	<brief_title>A Multi-centre , Double-blinded , Randomized , Placebo-controlled Trial Efficacy Safety Lopinavir / Ritonavir Plus Ribavirin Treatment Severe Acute Respiratory Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
	<mesh_term>Coronavirus Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Male female age 18 diagnosis SARS valid consent recruit . Subjects medical condition make prescription study medication unsafe exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Severe acute respiratory syndrome</keyword>
</DOC>